Pulsed Field Ablation of Atrial Fibrillation and Atrial Tachycardia in Adult Patients with Congenital Heart Disease: Results After Midterm Follow-Up
The Thoracic and Cardiovascular Surgeon · 2026-01 · 74 (S 02) · S71-S98
DOI: 10.1055/s-0046-1817385 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Thoracic and Cardiovascular Surgeon, online erschienen am 17.02.2026. Verfasst von U. Krause und 3 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window)
Background
Atrial fibrillation (AF) and atrial tachycardias (AT) are diagnosed with increasing prevalence in adults with congenital heart disease (ACHD). Pulsed field ablation (PFA) is a nonthermal energy source approved for catheter ablation of paroxysmal AF with promising mid-term effects. Data on the significance of PFA for catheter ablation in ACHD patients is scarce, particularly data on mid- and long-term outcomes are missing. We report our experience and first data on the midterm outcome of deploying PFA for catheter ablation of AT and AF in a single-center cohort of ACHD patients.
Methods
PFA was achieved using a multielectrode pulsed field ablation catheter, allowing for energy application either in a basket-like or in a flower-like configuration. High-density voltage maps and isochronal late activation maps (ILAM) were obtained prior to and after PFA. A force-sensing radiofrequency ablation catheter was used for additional radiofrequency ablation (RFA).
Results
A total of 48 consecutive patients with various types of congenital heart disease (CHD; mild CHD n = 9 (19%), moderate CHD n = 22 (46%), severe CHD n = 17 (35%) were enrolled between August 2022 and March 2025. Median age at ablation was 57 (IQR: 44–63) years, and median follow-up was 19 (IQR: 12–26) months. AF was indicated and targeted for PFA in 26 subjects (54%), AT was targeted in 13 patients (27%), and both AT and AF were targeted in 9 patients (19%). Additional RFA was used in 10 subjects (21%, thereof n = 8 cavotricuspid isthmus (CTI), n = 2 right atrial substrate other than CTI). Procedural success was achieved in all patients (100%). During follow-up, recurrence of either sustained AT or AF requiring cardioversion was reported in 10 subjects (21%). Procedural complications were reported in three subjects (6%): reversible spasm of the right coronary artery after PFA within the CTI ( n = 1), inguinal hematoma without need for surgery ( n = 1), and pericardial tamponade requiring drainage after transseptal puncture in a patient after ASD device closure ( n = 1).
Conclusion
Our data suggest advantages of PFA in the treatment of AF and difficult-to-treat AT with a comparatively low recurrence rate over a median follow-up period of > 1.5 years. Notably, no irreversible complications attributable to PFA were observed. Therefore, PFA might be superior to thermal energy sources for catheter ablation of AF/AT in the ACHD population. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Zitieren
APA
Krause, U., Diehl, C., Schneider, H., & Müller, M. (2026). Pulsed Field Ablation of Atrial Fibrillation and Atrial Tachycardia in Adult Patients with Congenital Heart Disease: Results After Midterm Follow-Up. The Thoracic and Cardiovascular Surgeon, 74(S 02), S71-S98. https://doi.org/10.1055/s-0046-1817385
Vancouver
Krause U, Diehl C, Schneider H, Müller M. Pulsed Field Ablation of Atrial Fibrillation and Atrial Tachycardia in Adult Patients with Congenital Heart Disease: Results After Midterm Follow-Up. The Thoracic and Cardiovascular Surgeon. 2026;74(S 02):S71-S98. doi:10.1055/s-0046-1817385
BibTeX
@article{Krause2026,
author = {Krause, U. and Diehl, C. and Schneider, H. and Müller, M.},
title = {Pulsed Field Ablation of Atrial Fibrillation and Atrial Tachycardia in Adult Patients with Congenital Heart Disease: Results After Midterm Follow-Up},
journal = {The Thoracic and Cardiovascular Surgeon},
year = {2026},
volume = {74},
number = {S 02},
pages = {S71--S98},
doi = {10.1055/s-0046-1817385}
}
EUVIMED